Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ARA NYSE:ARDT NASDAQ:CLOV NYSE:PHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAAmerican Renal Associates$11.52$11.50$5.57▼$11.98$397.94M1.11106,940 shs9,831 shsARDTArdent Health$10.21-3.7%$13.04$10.10▼$20.72$1.52BN/A470,005 shs470,053 shsCLOVClover Health Investments$2.78-3.8%$2.97$1.50▼$4.87$1.47B1.919.57 million shs7.37 million shsPHRPhreesia$26.31-2.4%$26.82$17.07▼$30.53$1.60B0.71441,135 shs433,179 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAAmerican Renal Associates0.00%0.00%0.00%0.00%0.00%ARDTArdent Health-3.42%-7.60%-24.09%-22.53%-42.93%CLOVClover Health Investments-3.81%-8.55%+7.34%-16.77%+45.55%PHRPhreesia-2.44%-1.16%-9.56%+2.49%+5.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARAAmerican Renal AssociatesN/AN/AN/AN/AN/AN/AN/AN/AARDTArdent Health3.6115 of 5 stars3.50.00.00.02.60.03.8CLOVClover Health Investments3.0068 of 5 stars3.33.00.00.03.32.50.6PHRPhreesia4.2023 of 5 stars3.53.00.04.22.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAAmerican Renal Associates 0.00N/AN/AN/AARDTArdent Health 2.92Moderate Buy$20.3098.82% UpsideCLOVClover Health Investments 2.67Moderate Buy$4.8373.86% UpsidePHRPhreesia 3.09Buy$32.2722.66% UpsideCurrent Analyst Ratings BreakdownLatest ARA, CLOV, PHR, and ARDT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025PHRPhreesiaDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/16/2025ARDTArdent HealthBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$15.50 ➝ $14.607/14/2025PHRPhreesiaKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$28.00 ➝ $35.005/29/2025PHRPhreesiaTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$34.00 ➝ $35.005/29/2025PHRPhreesiaCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$35.00 ➝ $34.005/28/2025PHRPhreesiaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/20/2025ARDTArdent HealthStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$21.00 ➝ $21.005/15/2025ARDTArdent HealthRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$21.00 ➝ $21.005/9/2025ARDTArdent HealthGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $18.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAAmerican Renal Associates$822.52M0.48$1.69 per share6.80$2.59 per share4.45ARDTArdent Health$5.97B0.24$2.44 per share4.18$10.66 per share0.96CLOVClover Health Investments$1.37B1.03N/AN/A$0.68 per share4.09PHRPhreesia$419.81M3.73N/AN/A$4.56 per share5.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAAmerican Renal Associates-$13.79M$0.26N/AN/AN/A-2.04%-3.56%-0.24%N/AARDTArdent Health$210.34M$1.636.265.214.443.73%16.07%4.69%8/5/2025 (Estimated)CLOVClover Health Investments-$43.01M-$0.05N/AN/AN/A-1.69%-7.42%-4.00%8/5/2025 (Estimated)PHRPhreesia-$58.53M-$0.74N/AN/AN/A-9.83%-16.23%-11.19%9/3/2025 (Estimated)Latest ARA, CLOV, PHR, and ARDT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ARDTArdent Health$0.51N/AN/AN/A$1.54 billionN/A8/5/2025Q2 2025CLOVClover Health Investments$0.03N/AN/AN/A$468.30 millionN/A5/28/2025Q1 2026PHRPhreesia-$0.13-$0.07+$0.06-$0.07$115.00 million$115.94 million5/6/2025Q1 2025ARDTArdent Health$0.21$0.29+$0.08$0.29$1.50 billion$1.50 billion5/6/2025Q1 2025CLOVClover Health Investments-$0.07$0.05+$0.12N/A$466.93 million$462.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARAAmerican Renal AssociatesN/AN/AN/AN/AN/AARDTArdent HealthN/AN/AN/AN/AN/ACLOVClover Health InvestmentsN/AN/AN/AN/AN/APHRPhreesiaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAAmerican Renal Associates7.541.051.02ARDTArdent Health0.702.121.98CLOVClover Health InvestmentsN/A1.541.54PHRPhreesia0.021.951.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAAmerican Renal Associates78.42%ARDTArdent HealthN/ACLOVClover Health Investments19.77%PHRPhreesia92.10%Insider OwnershipCompanyInsider OwnershipARAAmerican Renal Associates9.50%ARDTArdent Health1.70%CLOVClover Health Investments24.07%PHRPhreesia5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAAmerican Renal Associates4,97734.54 millionN/AOptionableARDTArdent Health24,900143.04 million140.61 millionOptionableCLOVClover Health Investments680508.92 million386.42 millionOptionablePHRPhreesia2,08259.50 million56.23 millionOptionableARA, CLOV, PHR, and ARDT HeadlinesRecent News About These CompaniesGSA Capital Partners LLP Lowers Stake in Phreesia, Inc. (NYSE:PHR)August 1 at 4:04 AM | marketbeat.comNew Research Illustrates Gaps in COPD Care and the Need for Better Patient-Provider CommunicationJuly 30 at 4:05 PM | businesswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Integer Holdings (ITGR), Phreesia (PHR) and Moderna (MRNA)July 30 at 4:31 AM | theglobeandmail.com5 Under-the-Radar Software-as-a-Service Companies for Your Growth Stock PortfolioJuly 29, 2025 | sg.finance.yahoo.comVictory Capital Management Inc. Takes $10.78 Million Position in Phreesia, Inc. (NYSE:PHR)July 25, 2025 | marketbeat.comStocks Generating Improved Relative Strength: PhreesiaJuly 23, 2025 | msn.comDA Davidson Upgrades Phreesia (NYSE:PHR) to Strong-BuyJuly 23, 2025 | marketbeat.comYvonne Hui Sells 465 Shares of Phreesia, Inc. (NYSE:PHR) StockJuly 22, 2025 | insidertrades.comYvonne Hui Sells 465 Shares of Phreesia, Inc. (NYSE:PHR) StockJuly 21, 2025 | marketbeat.comYvonne Hui Sells 626 Shares of Phreesia, Inc. (NYSE:PHR) StockJuly 21, 2025 | marketbeat.comAmy Beth Vanduyn Sells 640 Shares of Phreesia, Inc. (NYSE:PHR) StockJuly 21, 2025 | marketbeat.comBalaji Gandhi Sells 886 Shares of Phreesia, Inc. (NYSE:PHR) StockJuly 21, 2025 | marketbeat.comAllison C. Hoffman Sells 1,245 Shares of Phreesia, Inc. (NYSE:PHR) StockJuly 21, 2025 | marketbeat.comInsider Selling: Phreesia, Inc. (NYSE:PHR) COO Sells 1,892 Shares of StockJuly 21, 2025 | marketbeat.comInsider Selling: Phreesia, Inc. (NYSE:PHR) SVP Sells 2,063 Shares of StockJuly 21, 2025 | marketbeat.comPrincipal Financial Group Inc. Buys New Stake in Phreesia, Inc. (NYSE:PHR)July 20, 2025 | marketbeat.comPhreesia (NYSE:PHR) Stock Price Down 3.8% - What's Next?July 19, 2025 | marketbeat.comPhreesia, Inc. (NYSE:PHR) Insider Yvonne Hui Sells 422 SharesJuly 18, 2025 | marketbeat.comLisa Egbuonu-Davis Sells 465 Shares of Phreesia, Inc. (NYSE:PHR) StockJuly 18, 2025 | marketbeat.comPhreesia, Inc. (NYSE:PHR) Insider Sells $11,372.90 in StockJuly 18, 2025 | insidertrades.comAll You Need to Know About Phreesia (PHR) Rating Upgrade to BuyJuly 15, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerRocket Lab: A Parabolic Run Meets a Healthy PullbackBy Ryan Hasson | July 23, 2025View Rocket Lab: A Parabolic Run Meets a Healthy PullbackAs Bitcoin Hits New Highs, These 3 Stocks Could ExplodeBy Gabriel Osorio-Mazilli | July 21, 2025View As Bitcoin Hits New Highs, These 3 Stocks Could ExplodeARA, CLOV, PHR, and ARDT Company DescriptionsAmerican Renal Associates NYSE:ARAAmerican Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.Ardent Health NYSE:ARDT$10.21 -0.39 (-3.68%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$10.54 +0.32 (+3.18%) As of 08/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.Clover Health Investments NASDAQ:CLOV$2.78 -0.11 (-3.81%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.80 +0.02 (+0.54%) As of 08/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.Phreesia NYSE:PHR$26.31 -0.65 (-2.41%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$26.34 +0.03 (+0.10%) As of 08/1/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.